๐Ÿ”Ž Trials Near Me

Home โ€บ Ewing Sarcoma

Ewing Sarcoma clinical trials recruiting in the U.S.

33 studies for Ewing Sarcoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

RecruitingPhase 1
Ages 1 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07194044

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

RecruitingPhase 1
Ages 2 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07297979

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
6 Months โ€“ 25 Years ยท All sexes ยท Updated Sep 17, 2026 ยท NCT06395103

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

RecruitingPhase 1
Ages 12 to 85 ยท All sexes ยท Updated Sep 8, 2026 ยท NCT03715933

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

RecruitingPhase 1/2
Up to age 30 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06541262

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

RecruitingPhase 1/2
Up to age 26 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06465199

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

RecruitingPhase 1
Ages 5 to 40 ยท All sexes ยท Updated Sep 3, 2026 ยท NCT06156410

Lurbinectedin in FET-Fused Tumors

RecruitingPhase 1/2
Ages 10 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT05918640

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
12 Months โ€“ 30 Years ยท All sexes ยท Updated Aug 25, 2026 ยท NCT04851119

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

Recruiting
All ages ยท All sexes ยท Updated Aug 21, 2026 ยท NCT07514819

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

RecruitingPhase 1
Ages 1 to 23 ยท All sexes ยท Updated Aug 13, 2026 ยท NCT07172958

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 6, 2026 ยท NCT05210374

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Jul 31, 2026 ยท NCT07628634

Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

Recruiting
Up to age 39 ยท All sexes ยท Updated Jul 13, 2026 ยท NCT06796543

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

RecruitingPhase 2
Ages 0 to 50 ยท All sexes ยท Updated Jul 9, 2026 ยท NCT07321912

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

RecruitingPhase 1/2
6 Months โ€“ 25 Years ยท All sexes ยท Updated Jun 30, 2026 ยท NCT06625190

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Recruiting
Ages 2 and older ยท All sexes ยท Updated Jun 4, 2026 ยท NCT07188532

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

RecruitingPhase 1
Ages 16 and older ยท All sexes ยท Updated Jun 2, 2026 ยท NCT07197554

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
12 Months โ€“ 30 Years ยท All sexes ยท Updated May 19, 2026 ยท NCT04901702

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

RecruitingPhase 1
Up to age 21 ยท All sexes ยท Updated May 19, 2026 ยท NCT04897321

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

RecruitingObservational study
Ages 4 and older ยท All sexes ยท Updated Apr 17, 2026 ยท NCT03442465

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

RecruitingPhase 1
Ages 1 to 30 ยท All sexes ยท Updated Apr 15, 2026 ยท NCT04308330

Single Arm Romiplostim to Prevent CIT

RecruitingEarly phase 1
Ages 1 and older ยท All sexes ยท Updated Mar 18, 2026 ยท NCT07048249

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

RecruitingPhase 2
Ages 1 to 50 ยท All sexes ยท Updated Mar 13, 2026 ยท NCT01804634

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.